title: Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma.
authors: Division of Hematology Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan Division of Hematology Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, kmrau58@adm.cgmh.org.tw.
authors: Yu-Li
authors: YL
authors: Su
authors: Kun-Ming
authors: KM
authors: Rau
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D000077192:Adenocarcinoma of Lung; D000077548:Anaplastic Lymphoma Kinase; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D001932:Brain Neoplasms / Q000175:diagnosis / Q000556:secondary / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D014057:Tomography, X-Ray Computed
chemical_list: D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; D000068258:Bevacizumab; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases